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Cognitive deficits are now recognized widely as core features of schizophrenia, and as major contributors to the clinical outcome 
of the disorder. They are also studied widely as ‘endophenotypes’, reflecting a growing consensus that schizophrenia is a broader, 
more multidimensional illness than the diagnostic criteria required for its formal diagnosis. This evolving view of cognition un-
derlies its utilization in recent initiatives for intervention and assessment in schizophrenia. Two of these initiatives are reviewed in 
this paper. The first focuses on the development and validation of the MATRICS Cognitive Consensus Battery, a standardized 
battery of neuropsychological tests developed to assess the effectiveness of cognitive enhancing treatments in schizophrenia. A 
part of this effort includes the identification of performance-based, ‘co-primary’ measures of functional capacity that are related to 
cognition, and that are likely to show improvement at least partly as a function of improved cognition. The second initiative in-
volves efforts to utilize neuropsychological deficits in the identification, validation and remediation of a liability syndrome for 
schizophrenia (‘schizotaxia’). The discussion of this effort focuses on the development of a syndrome that is both measurable and 
meaningful clinically, and that may provide useful intervention targets. The utilization of cognition in both of these initiatives 
underscores its functional importance in the clinical outcome of schizophrenia. Moreover, it helps to illuminate indicators of lia-
bility for schizophrenia that might be amenable to remediation. 
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Although genetic contributions to schizophrenia are both 
well-accepted and compelling [1–4], the identity of most 
genes that increase susceptibility to the disorder — and the 
biological mechanisms by which they act — are largely 
unknown. One approach to understand how genetic deter-
minants of schizophrenia leads to the disorder capitalizes on 
the idea that schizophrenia is broader than the DSM-IV or 
ICD-10 syndromes that are required for its diagnosis [5]. 
The importance of identifying specific abnormalities (i.e. 
‘endophenotypes’) that reflect social, psychophysiological, 
neuropsychological, biological and other dimensions of 
dysfunction reflects a growing awareness that multidimen-
sional expressions of psychiatric disorders can advance the 
search for underlying etiological or modulatory factors 
[3,6–11]. Moreover, specific endophenotypes may be more 
amenable to objective measurement than symptoms, pre-
sumably reflecting variation among smaller numbers of 
genes than do more distal clinical symptoms [6,12,13], and 
are heritable [14,15]. These points all support the usefulness 
of endophenotypes in genetic studies [5,6,12,13,16–21].  
Among putative endophenotypes, examinations of neu-
ropsychological functions have shown some of the most 
robust deficits, especially in domains such as overall cogni-
tive ability (e.g. IQ), executive functions, sustained attention/ 
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vigilance and verbal declarative memory [22–25]. In addi-
tion to their potential roles in furthering an understanding of 
the genetic etiology of schizophrenia, neuropsychological 
endophenotypes are significant for clinical/functional rea-
sons. One of the most important of these are the effects of 
cognition on clinical and functional outcomes [26,27], such 
as the abilities to function in the community and to learn 
social skills. Notably, neuropsychological function are often 
unrelated to clinical symptom severity [28], and thus reflect 
different dimensions of function, at least in part. The mag-
nitude, breadth and functional significance of these dimen-
sions have important implications for the utilization of neu-
ropsychological endophenotypes, both in treatment and as-
sessment. This paper examines two of these implications. 
The first involves current attempts to develop a standardized 
battery of neuropsychological tests for use in clinical trials 
of cognitive enhancement. The second involves the use of 
putative neuropsychological endophenotypes in the devel-
opment of a liability syndrome to identify individuals at risk 
for developing schizophrenia, and to identify treatment tar-
gets to attenuate or even prevent the development of the 
disorder. 
1  Development of a standardized cognitive 
battery for schizophrenia studies construction of 
the MATRICS cognitive consensus battery  
The need to compare findings across studies gives rise to 
the need to develop a standardized battery of neuropsycho-
logical tests to use in clinical trials of cognitively enhancing 
treatments in schizophrenia. It especially reflects the diffi-
culties in interpretation that results from comparing differ-
ent tests, test orders and administration times, among other 
protocol differences between studies. This need was ad-
dressed in the (American) National Institute of Mental 
Health (NIMH) initiative to encourage the development of 
novel interventions to attenuate cognitive deficits in schiz-
ophrenia, called Measurement and Treatment Research to 
Improve Cognition in Schizophrenia (MATRICS), which 
included the development of a reliable, valid cognitive con-
sensus battery to use in clinical trials.  
The development of the MATRICS battery to this point 
has been well documented [29,30], and will be summarized 
briefly, in the context of salient issues concerning the nature 
and assessment of cognitive deficits in schizophrenia. Initial 
decisions about the nature and breadth of the battery were 
determined by a survey of 68 experts [31]. Significant is-
sues in this process were both practical and conceptual in 
nature. Practical concerns, for example, included the length 
of the battery, which led to a consensus that it should not 
exceed 90 min. Moreover, each test in the battery should not 
exceed 15 min, and should have good reliability and validity. 
The availability of comparable alternate forms for individual 
tests was important. Each test in the battery — and the bat-
tery itself — should be feasible for use in clinical trials of 
pharmacological agents with proposed cognition enhancing 
properties. To address these concerns, the battery needed to 
demonstrate good test-retest reliability, lend itself to re-
peated measurements, demonstrate acceptable degrees of 
tolerance for patients and show adequate sensitivity to 
change upon retesting, as a result of pharmacological inter-
ventions.  
Important conceptual issues were also considered, in-
cluding the type of tests to include in the battery. This issue 
is complicated for a number of reasons, including the broad 
range of cognitive deficits in schizophrenia. This range can 
be conceptualized in at least two ways. First, breadth of 
deficits can be considered to reflect a single generalized 
deficit, which might be reflected by measures that assess 
generalized functioning, such as Full Scale IQ scores de-
rived from Wechsler intelligence tests. Impairments in 
broad measures of cognition, however, also occur in the 
context of broad neuropsychological impairments across 
multiple domains. This raises the question of whether sepa-
rable cognitive deficits really occur in schizophrenia, or 
whether they reflect a more generalized or widespread deficit 
that is evident in whichever cognitive domain is assessed. 
Several studies present evidence for broad general factors 
[28]. Dickinson et al. [32] showed that 47% of the variance 
in a battery of cognitive tests was attributable to a schizo-
phrenia diagnosis, with 65% of this diagnosis-related find-
ing attributable to a single, common factor. A subsequent 
study showed that 63.6% of the diagnosis-related variance 
was attributable to a common factor, with much smaller 
percentages attributable to performance in other cognitive 
domains, such as verbal memory (13.8%) and processing 
speed (9.1%) [33]. The same group demonstrated that, 
compared to healthy controls, schizophrenia patients 
showed higher correlations between composite scores of 
neuropsychological functions in a study of confirmatory 
factor analysis, consistent with the hypothesis that patients 
demonstrated a more generalized cognitive ability (or defi-
cit) than controls [34].  
Nevertheless, these and other studies show that the 
choice between general and more specific cognitive abilities 
is not necessarily a mutually exclusive one, as both general 
and more specific cognitive deficits in schizophrenia occur 
simultaneously [32,35,36]. As importantly, the presence of 
one or more common cognitive factors does not mean that 
eventual treatments would affect all dimensions of cogni-
tion equally. Neuropsychological test performance in 
healthy control samples is often variable [37,38] and subject 
to dissociation (e.g., the patient H.M. developed profound 
temporal lobe amnesia following surgery for epilepsy, but 
retained intact immediate memory and above-average over-
all cognitive abilities [39]). Similarly, cognitive dysfunction 
is also likely to be dissociable, with potential treatments for 
schizophrenia influencing some dimensions of cognition 
more effectively than others.  
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As part of the effort to develop the MATRICS battery, 
evidence for separable cognitive factors was evaluated em-
pirically, with an emphasis on factor analytic studies [36]. 
This review yielded 7 distinct, replicated dimensions of 
cognitive dysfunction in schizophrenia, including: Speed of 
Processing, Attention/Vigilance, Working Memory, Verbal 
Learning and Memory, Visual Learning and Memory, Rea-
soning and Problem Solving, and Verbal Comprehension. 
Verbal Comprehension was considered inappropriate for 
inclusion in the battery because it was considered less likely 
than the other dimensions to change with treatment. Social 
Cognition was added to the list because of growing interest 
in this particular dimension of function, and because of a 
more general interest in understanding how changes in cog-
nition affect other functional domains. These seven domains 
were recommended for inclusion in the MATRICS-NIMH 
consensus cognitive battery (MCCB).  
Consideration of conceptual, psychometric and pragmat-
ic factors produced an initial candidate list of 90 tests, 
which were reduced to 36 tests in the seven cognitive di-
mensions described above [29]. These tests were then eval-
uated using the RAND/UCLA appropriateness method, 
which involves a series of steps that are applied iteratively 
to increase rater agreement among a panel of experts [40]. 
The panel consisted of experts in several relevant fields who 
rated the each test according to 5 criteria. These ratings 
were used to create a beta version of the battery that in-
cluded 20 tests that could be classified in 14 cognitive do-
mains. The MATRICS Psychometric and Standardization 
Study (PASS) was then conducted on a sample of patients 
with schizophrenia who were assessed at baseline and then 
again after 4 weeks, to develop a final version of the battery. 
Selection of tests for the final version was based on the psy-
chometric properties of the tests in the beta version (e.g., 
test-retest reliability, and utility as a repeated measure), 
their practicality, and their tolerability. Following a discus-
sion of each candidate test, experts on the MATRICS  
Neurocognition Committee rated them to select 10 tests for 
the final battery, which is shown in Table 1 along with the 
cognitive domains they represent. These cognitive domains 
were among those that were determined to be separable 
earlier [36]. Once the tests were selected, they were brought 
together into a single battery [41], with a website to facili-
tate acquisition and use of the battery (http: //www.matric- 
sinc.org). 
2  MATRICS co-norming and validation 
Once the individual tests were selected for the MATRICS 
battery, the psychometric properties of the battery itself 
were established. The basis of these studies involved the 
need to establish normative performance on the tests in the 
same battery, using the same normative source (i.e. 
co-norming). This step was essential because performance 
on individual tests in the MATRICS battery were normed 
originally on different samples with different characteristics 
[30]. In the absence of co-norming, performance on these 
tests cannot be compared with each other in a straightfor-
ward manner. Moreover, base rates of differences in per-
formance on different tests, expected levels of variability 
and even normative performance would be difficulty to es-
tablish, as would the development of composite scores or an 
overall unitary measure of performance. Consequently, 
performance on the MATRICS battery considered as a 
whole was compared in patients with schizophrenia to the 
performance of individuals recruited from the community, 
for the purpose of establishing normative levels of perfor-
mance [30]. The community sample was recruited to reflect 
representative geographic regions of the United States, and 
also representative distributions of age, gender, education 
and ethnicity. The data from this study was used to develop 
the MATRICS computer scoring program, and for options 
to include or not include demographic covariates (i.e. no 
covariates, age and gender covariates, or age, gender and 
education covariates). The results confirmed the prominent 
cognitive deficits in schizophrenia patients, and also showed 
consistently significant effects of age and education on per- 
Table 1  MATRICS cognitive consensus battery (MCCB)a)  
Test Cognitive domain 
1. Trail Making Test, Part A Speed of Processing 
2. Brief Assessment of Cognition in Schizophrenia (BACS): Symbol-Coding Speed of Processing 
3. Hopkins Verbal Learning Test — Revised (3 learning trials only)  Verbal Learning 
4. Wechsler Memory Scale — III (WMS-III): Spatial Span Working Memory (nonverbal) 
5. Letter-Number Span Working Memory (verbal) 
6. Neuropsychological Assessment Battery (NAB): Mazes Reasoning and Problem Solving 
7. Brief Visual Spatial Memory Test — Revised Visual Learning 
8. Category Fluency (Animal Naming) Speed of Processing 
9. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT): Managing Emotions Social Cognition 
10. Continuous Performance Test — Identical Pairs Attention/Vigilance 
a) Tests are listed in order of administration. Estimated administration time=63.5 min. 
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formance. Effects of gender varied more between individual 
tests. A recent follow-up study of this sample showed that 
the speed of processing and the social cognition domains 
best distinguished individuals with schizophrenia from the 
community sample [42]. The speed of processing, visual 
learning and attention/vigilance domains best distinguished 
individuals with schizophrenia who were competitively (i.e. 
gainfully) employed from those who were not.  
Validation studies involving the MATRICS battery have 
been encouraging. For example, the battery had been trans-
lated into 11 languages as of 2010 [43], and is being trans-
lated into more languages in 2011 for use in international 
trials. A recent, 29-site trial of the effects of two antipsy-
chotic medications administered to stable outpatients with 
schizophrenia in the United States confirmed that the 
MATRICS battery was sensitive to cognitive deficits, had 
good test-retest reliability and showed small practice effects 
[44].  
Another important initiative involves the development of 
‘co-primary’ measures to accompany the MATRICS battery. 
This effort derives from a position adopted by The U.S. 
Food and Drug Administration (FDA) that improvement on 
neuropsychological tests such as those in the MATRICS 
battery is a necessary, but not a sufficient condition for ap-
proval of a drug for cognitive enhancement in schizophrenia 
[45]. This position reflects the view that performance on 
cognitive measures is not related clearly enough to perfor-
mance of ‘real-world’ tasks. Consequently, the FDA re-
quired that pharmacological treatments for cognition must 
also improve performance on a functionally meaningful 
‘co-primary’ measure that has more face validity for con-
sumers and clinicians than neuropsychological tests.  
Methods for evaluating performance-based and inter-
view-based measures were developed as part of the PASS 
study [46]. The Validation of Intermediate Measures study 
(VIM) then utilized and extended these methods to deter-
mine the psychometric properties, utility and practicality of 
several potential co-primary measures [47]. One hundred 
and sixty-six patients with schizophrenia were assessed at 
baseline and 144 were retested 4 weeks later. Subjects re-
ceived clinical assessments, the MATRICS battery, and 
performance-based (the Independent Living Scales, the Test 
of Adaptive Behavior in Schizophrenia, and the UCSD 
Performance-based Skills Assessment) and interview-based 
(the Cognitive Assessment Interview and the Clinical Global 
Impression for Cognition) candidate co-primary measures. 
The performance-based measures had higher correlations 
with cognitive function than did the interview-based 
measures. Overall, the UCSD Performance-based Skills 
Assessment had the strongest overall properties, and the 
highest correlation with performance on the MATRICS 
battery (0.67). Full versions of the performance-based tests 
had better psychometric properties than short versions. 
Keefe and colleagues also showed a similar correlation be-
tween MATRICS performance and a brief version of the 
UCSD Performance-Based Skills Assessment [44].  
In a relatively short period, the MATRICS battery has 
become a standard measure for the assessment of cognition 
in schizophrenia, and particularly for the assessment of 
pharmacological treatments aimed at improving cognition in 
schizophrenia. Nevertheless, the extent of its utility and 
usefulness still requires additional validation. The likeli-
hood that MATRICS performance measures will serve as 
neuropsychological endophenotypes that might be useful for 
genetic studies, for example, is largely unexplored. It is also 
premature to conclude at this point when the MATRICS 
battery will be more or less useful than other cognitive bat-
teries in clinical trials of cognition enhancing drugs [48,49].  
The effort that went into its construction and validation, 
however, underscores a growing recognition of the func-
tional importance of cognition in schizophrenia outcomes, 
and of the possibility that cognitive deficits/endophenotypes 
could be viable treatment targets in the near future. Another 
critical area that involves neuropsychological endopheno-
types in particular and neuropsychological function in gen-
eral, is in the identification of liability for schizophrenia. 
One conceptualization of this liability, and its assessment, is 
considered next.  
3  Liability syndromes for schizophrenia  
3.1  Foundations of the concept 
The notion of liability to schizophrenia is not new. Bleuler 
[50] was among the first of many clinicians and researchers 
to note that individuals who develop schizophrenia often 
show abnormalities (e.g. interpersonal oddness or otherwise 
impaired social function) as children or adolescents, well 
before they develop schizophrenia. Family, twin and adop-
tion studies have long demonstrated that close biological 
relatives of individuals with schizophrenia show greater 
risks for developing schizophrenia or related disorders than 
the general population [1,51,52]. Evidence that a significant 
portion of this liability reflects a genetic etiology is compel-
ling at this point [1–4,53,54], and contributes to the con-
ceptualization of endophenotypes as heritable abnormalities 
that are associated with the disorder and that occur at ele-
vated rates in ‘unaffected’ relatives who share many genes 
with their ill relatives [6]. In this context, unusual behaviors 
in non-psychotic relatives of patients with schizophrenia 
were also observed frequently. Rado noted that “schizo-
types” and “schizotypal behaviors” resulted from a genetic 
liability to schizophrenia [55,56], which was integrated into 
a model proposed by Meehl [57,58] in which a major gene 
(a “schizogene”) produced a “neural integrative defect” that 
he referred to as “schizotaxia”. The underlying neural defect 
produced an observable phenotype called “schizotypy”, 
which is a type of personality organization that interacted 
with environmental variables such as social learning and 
other, polygenic factors (e.g., a predisposition to high or 
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low anxiety, or to different types of temperament). When 
the environment and other genetic circumstances were fa-
vorable in individuals who carried the schizogene, the ob-
servable phenotype would consist of only minor clinical 
symptoms (e.g., ‘compensated schizotypy’), but when other 
genetic and/or environmental circumstances were less fa-
vorable, then more severe, decompensated conditions would 
result, including schizophrenia.  
Over the next 3–4 decades, schizotaxia was used as a 
general term to describe the premorbid, neurological liabil-
ity for, and basis of, schizophrenia. In part because schizo-
taxia was unobservable directly in Meehl’s conceptualiza-
tion, it was not defined operationally or studied as a clinical 
syndrome. In contrast, Meehl’s conception of the most di-
rect consequence of schizotaxia — schizotypy — was con-
sidered observable, and that concept did enter the psychiat-
ric nosology in the modified form of ‘schizotypal personal-
ity disorder’. By the 1990s, however, a growing body of 
literature showed that a subset of non-psychotic relatives of 
people with schizophrenia showed a broad range of meas-
urable abnormalities in brain structure and function, neuro-
physiological aspects of information processing such as eye 
tracking and various sensory gating paradigms, neuropsy-
chological function, and social functioning, among others 
[7,8,17,59]. These findings supported the view that the no-
tion of liability might be amenable to operational definitions, 
whereas it had not been previously.  
Other factors contributed to the development of this idea. 
The focus on non-psychotic relatives, who could be studied 
without the confounding effects of psychosis, medication or 
chronic illness, produced a paradigm shift in the field [60], 
away from formal diagnostic clinical symptoms in patients, 
and towards biological, neuropsychological, social and oth-
er markers of schizophrenia disease. This shift focused re-
newed attention on endophenotypes, which helped to pro-
vide a conceptual understanding of the schizophrenia-  
related abnormalities that were identified in relatives [13]. 
As the focus shifted away from diagnostic criteria for 
schizophrenia, it also shifted away (somewhat) from psy-
chosis, and towards problems (e.g., neuropsychological 
deficits and social functioning deficits) that onset earlier 
than psychosis that might reflect the liability to develop 
schizophrenia. Longitudinal findings from genetic high risk 
studies showing neuropsychological, social/interpersonal 
and motor and abnormalities in the children of parents with 
schizophrenia that were associated with the development of 
subsequent psychosis, for example, were major contributors 
to this research [61,62]. In the same period, replications of 
genetic linkage studies gave new hope that eventually, sus-
ceptibility genes for schizophrenia might be identified, and 
would contribute to the early identification of individuals 
most at risk for developing schizophrenia [52]. Early identi-
fication, in turn, would facilitate early intervention efforts, 
and hopefully, at some point, prevention.  
Each of these lines of research promoted a broader view 
of schizophrenia than the DSM or ICD symptoms required 
to diagnose it. No strong, single predictor of schizophrenia 
emerged from this research, however, to predict the devel-
opment of the disorder reliably [63]. Many abnormalities 
that show predictive power when studied retrospectively are 
nonspecific, and are likely to contribute to elevated false 
positive rates and lower levels of specificity [20]. Moreover, 
even subjects who demonstrate positive symptoms (as 
demonstrated by elevated Scale of Prodromal Symptoms 
(SOPS) scores, for example) may remit or otherwise do not 
progress to develop schizophrenia [64–66]. A more accurate 
approach may involve the use of multiple measures or com-
binations of measures [67,68], but the prediction of schizo-
phrenia, particularly for individuals, remains at an early 
stage of development.  
3.2  Development and validation 
In this broad context, we reformulated the term schizotaxia 
in the 1990s to integrate newer data [59]. Our conception of 
schizotaxia was consistent with Meehl’s view of it as the 
underlying liability among people predisposed to schizo-
phrenia, though aspects of his view were modified. Perhaps 
most importantly among these differences, we proposed a 
provisional, operational definition of schizotaxia [69] that 
allows the concept to be validated or disconfirmed experi-
mentally. At this point, the proposed syndrome applies to 
adult, non-psychotic, biological, first-degree relatives of 
individuals with schizophrenia. The initial research criteria 
involved a subset of theoretically important symptoms/  
deficits that were relatively well-studied at the time, includ-
ing negative symptoms and specific deficits in neuropsy-
chological functioning. Negative symptoms were included 
because they (flat affect and avolition especially) are often 
elevated in families with a schizophrenic member, in con-
trast to positive symptoms [e.g., 70]. In this view, negative 
symptoms in schizotaxia are essentially the same as nega-
tive symptoms in DSM-IV schizotypal personality disorder. 
In this sense, they represent a ‘negative schizotypy’ dimen-
sion, without the positive (or disorganized) dimension that 
together constitutes the DSM-IV disorder [71]. In our pilot 
studies, anhedonia (e.g., few interests or sources of pleasure) 
and asociality (e.g., few romantic relationships or close 
friends) were among the most common negative symptoms 
observed in individuals with schizotaxia [69].  
Our initial criteria for schizotaxia also included neuro-
psychological deficits in verbal memory, attention and/or 
executive functions. Deficits in these neuropsychological 
domains are core features of schizophrenia that also occur 
frequently in relatives [7,23,72–75]. In addition to negative 
symptoms and cognitive deficits, several inclusion and ex-
clusion criteria were intended to minimize false positive 
diagnoses (e.g., negative symptoms or cognitive problems 
due to known neurological or medical conditions, current 
substance dependence, history of electroconvulsive treat-
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ment, or English spoken as a second language), and subjects 
with any lifetime history of a psychotic disorder [69]. Using 
these provisional, conceptually-based criteria, we assessed a 
group of 27, non-psychotic, first degree relatives of indi-
viduals with schizophrenia [76]. Eight subjects met criteria 
for schizotaxia, and 19 did not. Comparisons between the 
two groups were made on several relatively independent, 
non-criterion clinical measures, including the Social Ad-
justment Scale (SAS) [77], the DSM-IV Global Adjustment 
Scale (GAS) [78], and the Symptom Checklist-90-Revised 
(SCL-90-R) [79], among others. The groups did not differ 
in age, education, paternal education, IQ or number of ill 
relatives. The comparisons demonstrated evidence of con-
current validity for the concept by showing that relatives 
who met criteria for schizotaxia also showed poorer func-
tioning on these clinical measures compared to relatives 
who did not meet criteria, regardless of whether the 
measures were self-rated or rated (blindly) by the research-
ers.  
As part of an attempt to determine whether symptoms of 
schizotaxia were amenable to intervention, we also admin-
istered a low dose of risperidone (0.25 to 2.0 mg) to 6 of the 
8 subjects who met the schizotaxia criteria, and who agreed 
to a six-week, open-label course of the drug. Institutional 
oversight was provided by the Institutional Review Board 
(IRB) of the Massachusetts Mental Health Center (Boston, 
Massachusetts, USA). All subjects completed the protocol. 
Side effects were temporary and mild, and no abnormal 
movements were observed. Five of the 6 subjects showed 
improvement on a demanding test of auditory-verbal work-
ing memory, and showed reductions (25% to 50%) in the 
number of negative symptoms rated as at least moderate (i.e. 
scores of 3 or higher) on the Scale for Assessment of Nega-
tive Symptoms (SANS) [80].   
The results of the pilot validation study and the response 
to the pharmacological probe were encouraging, and led to a 
larger investigation designed to replicate or modify the 
proposed liability syndrome in adult, non-psychotic, first- 
degree biological relatives. Although the pilot study was 
conducted in Boston, the subsequent study was conducted at 
the Mental Health Institute, Second Xiangya Hospital of 
Central South University, Changsha, Hunan Province, Peo-
ple’s Republic of China, and will be referred to as the 
‘Changsha Study’ (Stone et al., submitted). The change in 
location reflected both the challenges involved in recruiting 
subjects locally who met our provisional criteria, and the 
opportunity to recruit appropriate subjects through collabo-
rators who were working with larger numbers of schizo-
phrenia families. 
The clinical (negative symptoms) and neuropsychologi-
cal domains used to assess schizotaxia were the same in the 
Changsha study as they were in the Boston pilot study. In-
dividual neuropsychological tests, however, were changed, 
because most of the criterion tests used in Boston did not 
have normative values for Chinese samples. The criteria 
used in the pilot study with the measures we employed were 
stringent, but were effective in identifying almost a third of 
the first group of relatives we assessed (8/27) as meeting 
criteria for schizotaxia. These criteria identified a much 
lower percentage of relatives in the Chinese sample, using 
the modified battery of tests with Chinese norms. Conse-
quently, we modified the criteria to make them less strin-
gent, but we also performed cluster analyses to determine 
whether our two-group classification of relatives into schiz-
otaxic and non-schizotaxic groups cohered empirically. In 
addition to the criterion measures, subjects also received 
additional measures of clinical, social, neuropsychological 
and medical function.  
One hundred and eighty-nine relatives were assessed, 
along with 30 community comparison subjects (CCS). Us-
ing the modified, conceptually-based criteria, 86 subjects 
were classified as having schizotaxia (45.5%), while 103 
were not. In general, relatives classified as non-schizotaxic 
performed similar to the CCS group. Relatives classified as 
schizotaxic showed significantly lower/poorer performance 
on a variety of criterion-related and non-criterion-related 
neuropsychological, clinical and social measures, including 
the GAF and the SAS. Results of the cluster analysis con-
firmed the two-group solution, and confirmed the classifica-
tion of most of the subjects. It did, however, reduce the 
number of subjects classified as schizotaxic from 86 to 53 
(28.0%), making it similar to the percentage we obtained in 
our pilot study in Boston, and it increased the non-schizo- 
taxic relatives group to 135. The cluster-derived groups 
showed the same pattern of relationships as the conceptually 
determined groups, but the effect sizes of several group dif-
ferences increased, including the GAF and the SAS. 
Subjects classified with schizotaxia were also recruited 
into a six-week intervention trial that involved administra-
tion of low doses of risperidone (0.25 to 2.0 mg) (Stone et  
al., submitted). Unlike our open-label pilot study, the trial 
utilized a double-blind, placebo-controlled design. Thirty-six 
of the 86 subjects who met criteria for schizotaxia agreed to 
enter the trial, of whom 20 were randomized to the risperi-
done group, and 16 were randomized to the placebo group. 
Side effects were mild and well tolerated generally, but one 
subject receiving risperidone did stop taking it 2 d before 
the completion of the protocol. The first set of data analyses 
focused on the criterion measures for schizotaxia, the non- 
criterion neuropsychological measures, and some of the 
non-criterion clinical measures, including the GAF and the 
SAS. The results showed significant improvement in the 
risperidone group in the criterion measures for executive 
function (i.e. fewer perseverative errors on the Wisconsin 
Card Sorting Test), and better self-rated social function on 
the SAS. The GAF scores did not change. The SANS scores 
did not change, either, which emphasizes the importance of 
follow-up initial findings obtained using open-label designs 
with more rigorous, double-blind protocols.  
Overall, these results are encouraging, and emphasize the 
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potential importance of cognition in the assessment of lia-
bility for schizophrenia. It should also be emphasized, 
however, that progress towards the identification of a liabil-
ity syndrome for schizophrenia remains in the early stages 
of development. The use of different neuropsychological 
tests in the Boston and the Changsha samples, and the re-
sults of the cluster analysis, emphasize the provisional na-
ture of the criteria at this point. The question of how to in-
tegrate other dimensions of function into a liability syn-
drome (e.g., structural and functional brain abnormalities, 
and electrophysiological deficits) remains an unexplored 
issue, as is the even greater fundamental question it raises 
about whether the liability for schizophrenia is best con-
ceptualized as a single, large syndrome in which many 
symptoms may or may not appear in a particular individual, 
or whether there are really many liability syndromes that 
could be defined and validated. The results of the risperi-
done study also require caveats. Only some measures 
changed with treatment, which could have occurred by 
chance, and which will necessitate additional replication. 
Although our findings are potentially significant in showing 
that neuropsychological and other symptoms related to the 
liability for schizophrenia may be amenable to intervention, 
they do not provide sufficient justification for the clinical 
use of antipsychotic medications — and their potential 
medical and psychosocial side effects — in preventive roles 
at this time.  
4  Discussion and conclusions  
Schizophrenic illness is associated with numerous neuro-
psychological abnormalities that are not related formally to 
DSM-IV or ICD-10 diagnostic criteria for schizophrenia or 
for other disorders in the schizophrenia spectrum. Many of 
these abnormalities meet some or all criteria proposed for 
endophenotypes, and are core features of schizophrenic ill-
ness. The importance of these cognitive abnormalities is 
emphasized in the two types of initiatives discussed in this 
review. The first of them involves the development of the 
MATRICS battery for use in clinical trials of treatments that 
might affect cognition. The second involves efforts to iden-
tify the liability to schizophrenia. Both of these initiatives 
share features in common that reflect the evolution of 
thinking in the field. The most fundamental similarities in-
clude recognition of the importance of cognition in clinical 
outcome, and in measuring liability. In schizophrenia itself, 
cognition is a major determinant, for example, of whether 
individuals can perform activities of daily living, live inde-
pendently, or work. In individuals at high risk for schizo-
phrenia, cognition is an important predictor of whether they 
will develop psychosis. Moreover, these initiatives empha-
size the functional importance of cognition in relation to 
clinical measures and to other measures of functional ca-
pacity.  
The initiatives emphasized here also reflect another im-
portant development. Until recently, the possibility of ame-
liorating cognitive deficits in schizophrenia has seemed 
slight [28,83,84]. Both of the initiatives discussed here, 
however, reflect an evolving view that specific cognitive 
measures may serve as useful, viable treatment targets for 
efforts to remediate cognitive weaknesses in schizophrenia. 
These targets are evident once psychosis develops, but they 
may also be very important prior to the onset of psychosis.  
Future research will be needed to continue to validate the 
utility of potential individual cognitive measures, as well as 
to validate the performance of batteries such as MATRICS 
and putative liability syndromes as a whole. These include 
their epidemiological properties such as base rates, their 
sensitivity to detect truly affected individuals, their specific-
ity to reject truly unaffected individuals, and their sensitivi-
ty to change with intervention. Another critical area in-
volves the need to understand further how cognition is re-
lated to other dimensions of schizophrenic illness, including 
both positive and negative symptoms, but also social, bio-
logical, genetic and other dimensions of function. The in-
clusion of cognition in broader consortium and other col-
laborative efforts to assess interrelationships across multiple 
dimensions of function will provide important catalysts for 
progress in each individual dimension. Hopefully, the 
growing emphasis on cognition in schizophrenia that is re-
flected by the recent initiatives discussed above will facili-
tate progress in both diagnosis and intervention in ways that 
will materially improve clinical outcomes.  
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